We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Multiplex Panels Quickly Supplanting Conventional Pathogen Detection Methods, Finds Report

By LabMedica International staff writers
Posted on 28 Sep 2023
Print article
Image: AMP has published a report on the use of multiplex panels for diagnosing infectious diseases (Photo courtesy of AMP)
Image: AMP has published a report on the use of multiplex panels for diagnosing infectious diseases (Photo courtesy of AMP)

Multiplex molecular panels are increasingly being adopted in clinical labs for detecting a variety of microbial pathogens in different settings. While a lot of data exists on their effectiveness in identifying respiratory pathogens, there is scant information available for other types. Now, the latest review provides valuable insights into the use of multiplex PCR panels for detecting pathogens in the gastrointestinal system, central nervous system, lower respiratory tract, and joint specimens. The review not only explores new methods for detecting pathogens in alternative types of specimens but also outlines challenges related to the implementation of new tests and the costs involved.

The Association for Molecular Pathology (AMP, Rockville, MD, USA) has published a review of the benefits and challenges in utilizing multiplex PCR panels for detecting microbial pathogens from gastrointestinal, central nervous system, lower respiratory tract, and joint specimens. The manuscript, “Exploring the Utility of Multiplex Infectious Disease Panel Testing for Diagnosis of Infection in Different Body Sites: A Joint Report of the Association for Molecular Pathology, American Society for Microbiology (ASM), Infectious Diseases Society of America (IDSA), and Pan American Society for Clinical Virology (PASCV),” has been released online ahead of publication in The Journal of Molecular Diagnostics.

Despite the apparent benefits and growing adoption of PCR multiplex panels, several questions still remain unanswered. For example, how exhaustive should the panel be to realize the advantages previously described? Is it more useful to have extensive multi-target panels, or is a specific subset of organisms sufficient for routine testing? Additionally, what is contributing to better patient outcomes—quicker test results or a more systematic approach that balances costs and patient benefits? These issues require more investigation as our understanding of the clinical utility of PCR multiplex panels continues to develop.

“Molecular multiplex panels are quickly supplanting conventional pathogen detection methods,” said Michael A. Lewinski, PhD, Chair of the AMP Infectious Diseases Multiplex Working Group. “This new report offers a detailed snapshot of the various clinical and analytical benefits and challenges associated with these panels for diagnosis of infection in different body sites. We also raise a few questions that warrant further study.”

Related Links:
AMP

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.